Compare ENOV & PAHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENOV | PAHC |
|---|---|---|
| Founded | 1995 | 1946 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Fluid Controls | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | 2008 | 2014 |
| Metric | ENOV | PAHC |
|---|---|---|
| Price | $25.55 | $35.61 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 9 | 4 |
| Target Price | ★ $47.38 | $41.25 |
| AVG Volume (30 Days) | ★ 1.0M | 358.7K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 0.91% |
| EPS Growth | N/A | ★ 1883.33 |
| EPS | N/A | ★ 1.90 |
| Revenue | N/A | ★ $833,350,000.00 |
| Revenue This Year | $6.36 | $17.03 |
| Revenue Next Year | $5.31 | $3.82 |
| P/E Ratio | ★ N/A | $18.59 |
| Revenue Growth | N/A | ★ 4.12 |
| 52 Week Low | $21.00 | $22.71 |
| 52 Week High | $36.82 | $60.08 |
| Indicator | ENOV | PAHC |
|---|---|---|
| Relative Strength Index (RSI) | 56.03 | 25.35 |
| Support Level | $21.52 | $25.58 |
| Resistance Level | $26.72 | $41.62 |
| Average True Range (ATR) | 1.40 | 3.16 |
| MACD | 0.20 | -2.35 |
| Stochastic Oscillator | 63.25 | 1.01 |
Enovis Corp is a medical technology manufacturer and distributor of medical devices used in reconstructive surgery, rehabilitation, pain management, and physical therapy. Its products support patient care from injury prevention through post-surgical or post-injury rehabilitation and treatment of degenerative conditions. The company's reportable segments include Prevention & Recovery and Reconstructive segments. The majority of revenueis derived from the Prevention & Recovery segment, which includes products that are used by orthopedic specialists, primary care physicians, physical therapists, chiropractors, athletic trainers and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformitiesand sports-related injuries.
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.